N-SIDE Secures Over €10M Investment to Drive Strong Growth Aspirations

Louvain-la-Neuve, Belgium, 29 March 2021 | N-SIDE, a pioneer in Data Analytics, Machine Learning and AI, announces an acceleration of its development and a global investment of more than €10 million to support its international expansion.

Significant milestones:

• N-SIDE’s turnover will approach €20 million in 2021: up by more than 40%;
• N-SIDE has registered a continuous increase of more than 40% in its turnover and a third in its workforce in recent years;
• Objective for the next 5 years: accelerate this growth in turnover and recruitment;
• The investment of more than €10 million reflects largely the commitment of the group’s investors and employee shareholders.

The Louvain-la-Neuve-based company N-SIDE is staying the course despite the crisis. Today it officially announces an additional investment of over €10 million.

It aspires to:

• accelerate the development of products for key sectors (the energy and pharmaceutical industry) and for new customers;
• guide and support the company’s ramp-up in product deployment (marketing and sales);
• conquer new international markets and consolidate the group’s expansion in the US market.

Active in North America for several years now, N-SIDE is already present in Cambridge (Massachusetts), with an office staffed with some ten employees since 2020. The next step is to establish a presence on the West Coast of the United States: “We have enormous potential for growth there, especially in the Life Sciences sector,” explains Jacques Parlongue, CEO of N-SIDE.

More than half of the world’s major pharmaceutical groups now use N-SIDE technologies – an exceptional penetration rate that confirms the power of the tools developed. “Our SaaS platform offers a more accurate view of future clinical trials, by bringing to bear optimal management of stocks and the distribution network — An area whose critical nature has never been more apparent in the midst of a global pandemic,” Jacques Parlongue says.  “We can now bring these technologies to smaller companies, where the R&D departments are generally smaller, but where we can provide end-to-end clinical trial management. “

N-SIDE’s vision for the coming years is to:

• continue to strengthen its impact and develop SaaS solutions based on cutting-edge technologies (artificial intelligence, algorithms and machine learning);
• provide accessible and innovative tools with a high ROI in the Life Sciences and the Energy sector.

The additional investment of more than €10 million was made with N-SIDE’s historical shareholders and financial partners. “This is a special as well as exceptional situation, where all of our historical investors participated,” says Jacques Parlongue. “We are inviting our own employees to this financing roundtable, so they can become stakeholders in our growth. Eventually, 20% of our employees will participate in the capital.” This is an inclusive development for the company, which will have 150 employees worldwide by the end of 2021 representing 25 nationalities already.

Quotes from the Board of Directors:

“This capital increase will enable N-SIDE to continue its rapid development so as to provide innovative solutions to the major challenges of managing energy networks to cope with the energy transition and optimizing clinical trials to develop new medical treatments.” Philippe Chevalier, President of N-SIDE.

“It is ever so exciting to participate in the creation of a world-class Belgian flagship. N-SIDE has a considerable impact in energy transition and pharmaceutical research.” François le Hodey, Member of the Board of Directors of N-SIDE.

“We had the opportunity to join N-SIDE’s shareholding 5 years ago at the end of a difficult phase. We were charmed by the quality of the vision, the entrepreneurial drive of the team and the technology. And we were not disappointed, as growth has been phenomenal these last few years. For us this is an indication that N-SIDE brings real solutions to its customers and an answer to important societal issues such as energy consumption and drug development. We are therefore delighted to continue to support N-SIDE with this capital increase.” Gaëtan Hannecart, Member of the Board of Directors of N-SIDE.

Meet the N-SIDE Board of Directors online.

——–

About N-SIDE

N-SIDE is an innovative software consulting company in advanced analytics designing optimization solutions for Life Sciences and Energy management. From strategy down to operations, N-SIDE leverages the value of your data and business knowledge into decision-making power. Our cloud-based custom solutions use cutting-edge technologies such as machine learning and powerful algorithms to solve the most complex industry challenges and turn them into opportunities. We empower organizations with agility and data-driven decisions to optimize processes and use resources wisely while efficiently managing risk and maximizing profits. We ensure our customers are ahead of the game! N-SIDE optimizes decisions of some of the largest companies around the world, across a vast range of industries: Pharmaceuticals, Power Exchanges, TSO’s and DSO’s, etc.

N-SIDE is ranked #5 in the Best Workplace™ of the Great Place to Work® Institute Belgium among companies with fewer than 500 employees.  True to its commitment, N-SIDE intends to distinguish itself among companies where the will to work for a more sustainable world takes priority. 

N-SIDE is a Certified B Corporation™. It means we meet the highest standards of verified social and environmental performance, accountability and transparency to balance purpose and profit.

Corporate contact

We are at your entire disposal for more information, interview requests or official photos and illustrations.

Pauline Martin 
Marketing Director, N-SIDE
pauline.martin@n-side.com

Justin Gellezak
Marketing Coordinator, N-SIDE
jge@n-side.com